Shelter Pharma (543963) Q4 18/19 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 18/19 earnings summary
23 Oct, 2026Executive summary
FY19 revenue from operations was ₹277.31m, down from ₹314.64m in FY18; net profit rose to ₹0.60m from ₹0.54m.
Auditors gave an unqualified opinion, concluding the statements presented a true and fair view of financial position and results.
Financial highlights
Total income was ₹277.52m versus ₹314.75m; other income increased to ₹0.20m from ₹0.10m.
Total expenses were ₹276.71m, down from ₹314.06m; raw material costs were ₹258.76m versus ₹291.06m.
Profit before tax increased to ₹0.803m from ₹0.690m; tax expense was ₹0.201m versus ₹0.146m, resulting in net profit of ₹0.602m versus ₹0.544m.
No exceptional or extraordinary items were reported for FY19.
Key financial ratios and metrics
Profit before interest, depreciation and tax was ₹1.984m, up from ₹1.681m; finance cost was nil in both years.
Basic and diluted EPS were ₹1.32 each, compared with ₹1.20 each in FY18.
Latest events from Shelter Pharma
- Revenue and net profit rose in FY18; profits were retained and no dividend recommended.543963
Q4 17/18 - Revenue and PAT rose in FY20 as factory expansion advanced; Rs 3 crore of advances were written off.543963Q4 19/20
- COVID disruption cut sales as FY21 profit fell; ₹30 lakh of old advances was written off.543963Q4 20/21
- FY22 revenue and profit rose sharply, while COVID disruptions remained a sales risk.543963Q4 21/22
- FY23 profit rose, while receivables climbed and an IPO of up to ₹350m advanced.543963Q4 22/23
- Strong revenue and profit growth, full utilization of raised funds, and clean audit opinion.543963Q4 25/26
- Revenue and profit increased year-over-year, with all raised funds used as intended.543963Q2 25/26
- Revenue and net profit grew year-over-year, with EPS rising to ₹3.06.543963Q2 24/25
- Revenue and net profit rose year-over-year, with robust financials and new auditor appointments.543963Q4 24/25